141 related articles for article (PubMed ID: 9164418)
21. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
[TBL] [Abstract][Full Text] [Related]
22. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
23. [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity].
Yano A; Hashimoto K; Okuchi T; Mizoguchi H; Mutaguchi K; Nakamoto T; Usui T
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1877-83. PubMed ID: 11729480
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group.
Bodsworth NJ; Boag F; Burdge D; Généreux M; Borleffs JC; Evans BA; Modai J; Colebunders R; Thomas M; DeHertogh D; Pacelli L; Thomis J
J Infect Dis; 1997 Jul; 176(1):103-11. PubMed ID: 9207355
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
[TBL] [Abstract][Full Text] [Related]
26. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster.
De Clercq E
Biochem Pharmacol; 2004 Dec; 68(12):2301-15. PubMed ID: 15548377
[TBL] [Abstract][Full Text] [Related]
27. Dihydropyrimidine dehydrogenase deficiency in an Indian population.
Saif MW; Mattison L; Carollo T; Ezzeldin H; Diasio RB
Cancer Chemother Pharmacol; 2006 Sep; 58(3):396-401. PubMed ID: 16421754
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
[TBL] [Abstract][Full Text] [Related]
29. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
30. Viremia in acute herpes zoster.
Satyaprakash AK; Tremaine AM; Stelter AA; Creed R; Ravanfar P; Mendoza N; Mehta SK; Rady PL; Pierson DL; Tyring SK
J Infect Dis; 2009 Jul; 200(1):26-32. PubMed ID: 19469706
[TBL] [Abstract][Full Text] [Related]
31. Tumor dihydropyrimidine dehydrogenase activity in advanced cervical carcinoma.
Nagai N; Shiroyama Y; Oshita T; Mukai K; Shigemasa K; Fujii T; Katsube Y; Matsubayashi S; Murakami T; Ohama K
Oncol Rep; 2002; 9(5):1033-40. PubMed ID: 12168069
[TBL] [Abstract][Full Text] [Related]
32. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
33. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
34. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Balzarini J; Sienaert R; Liekens S; Van Kuilenburg A; Carangio A; Esnouf R; De Clercq E; McGuigan C
Mol Pharmacol; 2002 May; 61(5):1140-5. PubMed ID: 11961132
[TBL] [Abstract][Full Text] [Related]
35. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
[TBL] [Abstract][Full Text] [Related]
36. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
Ahmed FY; Johnston SJ; Cassidy J; O'Kelly T; Binnie N; Murray GI; van Gennip AH; Abeling NG; Knight S; McLeod HL
J Clin Oncol; 1999 Aug; 17(8):2439-45. PubMed ID: 10561307
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
38. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
39. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
Ashida N; Ijichi K; Watanabe Y; Machida H
Biochem Pharmacol; 1993 Dec; 46(12):2201-7. PubMed ID: 8274153
[TBL] [Abstract][Full Text] [Related]
40. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
Van Kuilenburg AB; van Lenthe H; Blom MJ; Mul EP; Van Gennip AH
Br J Cancer; 1999 Feb; 79(3-4):620-6. PubMed ID: 10027339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
